The application value of contrast-enhanced computed tomography in cervical lymph node metastasis of oral carcinomas: A protocol for systematic review and meta-analysis.

BACKGROUND: Oral carcinomas is a concerning condition around the world. Globally, it is the 11th most common form of cancer. Over 90% of oral carcinomas are squamous cell carcinomas. Smoking, tobacco intake, smokeless tobacco (snuff or chewing tobacco), excessive sunlight exposure, alcohol, betel nut consumption, human papillomavirus, and reverse end smoking are the most common causes of oral carcinomas. Oral carcinomas are prone to neck lymph mode metastasis, which has an impact on the prognosis of patients and the five-year survival rate. Thus, precise lymph node metastasis and staging of oral carcinomas are critical. With the development of nuclear medicine and molecular imaging, an increasing number of studies have found that Contrast-Enhanced Computed Tomography (CECT) has high diagnostic value for tumors. METHODS AND ANALYSES: The reviewers will conduct a thorough search for related literature in 6 online databases, including The Cochrane Library, PubMed, WanFang database, Web of Science, Chinese biomedical literature database, and the China National Knowledge Infrastructure. The authors will obtain full text of studies deemed to be eligible to extract and synthesize data. The present systematic review will be reported in accordance with the Preferred Reporting Project (PRISMA-P) of the 2015 System Review and Meta-Analysis Protocol. RESULTS: The present systematic analysis will pool the results of individual studies to assess the value of CECT in cervical lymph node metastasis of oral carcinomas. CONCLUSION: The results in the proposed research will determine whether CECT is an efficient diagnostic method for cervical lymph node metastasis of oral carcinomas. ETHICS AND DISSEMINATION: This study will utilize secondary data from pre-published studies. Therefore, an ethical clearance is not required. The research outcomes shall be disseminated in conference reports and peer-reviewed publications. OSF REGISTRATION NUMBER: Oct 13, 2021.osf.io/k5nr9. (https://osf.io/k5nr9/).

Double-blind, randomized, controlled clinical trial of the effects of diosmectite and basic fibroblast growth factor paste on the treatment of minor recurrent aphthous stomatitis.

OBJECTIVE: This study investigated the effectiveness and safety of topical application of diosmectite (DS) and basic fibroblast growth factor (bFGF) paste in the treatment of minor recurrent aphthous stomatitis. STUDY DESIGN: Four pastes, containing bFGF and DS, DS alone, bFGF alone, and vehicle only, were consecutively applied 4 times per day for 5 days. Pain levels and the amount of ulcer amelioration were evaluated. RESULTS: A total of 129 participants completed the study. DS+bFGF paste released bFGF continuously and significantly lowered ulcer pain scores (P < .05 for days 3, 4, 5, and 6) compared with the other pastes. The ulcer size was significantly reduced (P < .05 for days 2, 4, and 6) in the DS+bFGF paste group compared with the other groups. No obvious adverse drug effects were observed. CONCLUSIONS: DS+bFGF paste was effective in alleviating ulcer pain and promoting healing without significant side effects in the treatment of minor recurrent aphthous stomatitis.

Efficacy of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis.

OBJECTIVE: The aim of this study was to investigate the effectiveness of triamcinolone acetonide (TA) and salvianolic acid B (SA-B) intralesional combined injection in the treatment of oral submucous fibrosis (OSF). MATERIAL AND METHODS: A randomized clinical trial was performed. TA, SA-B, and TA combined with SA-B were consecutively applied intralesionally weekly for 20 weeks. Mouth opening and burning sensation improvement as determined by a 100-mm visual analog scale were evaluated at weeks 10, 20, and 44. RESULTS: Forty-two subjects fulfilled the study without obvious adverse reactions. The net gain in mouth opening was 2.00 ± 1.21 mm in the TA group, 3.48 ± 2.23 mm in the SA-B group, and 5.50 ± 1.80 mm in the TA + SA-B group at week 44. The burning sensation improved by 3.05 ± 0.76 in the TA group, 4.96 ± 0.97 in the SA-B group, and 6.11 ± 0.93 in the TA + SA-B group by the end of the study. CONCLUSIONS: TA + SA-B intralesional injections improved mouth open and burning sensation in these OSF patients.

Clinical evaluation of allicin oral adhesive tablets in the treatment of recurrent aphthous ulceration.

OBJECTIVE: We investigated the effectiveness and safety of topical application of 5 mg allicin adhesive tablets in the treatment of minor recurrent aphthous ulcerations (MiRAU). MATERIAL AND METHODS: A randomized, double-blinded, placebo-controlled, clinical trial was performed. Tablets containing 5 mg allicin or vehicle only were consecutively applied 4 times per day for 5 days. The size and pain level of ulcers were measured and recorded on days 1, 2, 4, and 6. RESULTS: A total of 96 subjects with MiRAU fulfilled the study. Allicin adhesive tablets significantly reduced ulcer size (P < .005, P < .003, P < .001 for days 2, 4, and 6, respectively) and alleviated ulcer pain score (P < .03, P < .001, P < .05 for days 2, 4, and 6, respectively) compared with vehicle tablets. Minor and major adverse reactions were not observed. CONCLUSIONS: Allicin adhesive tablets were effective in reducing ulcer size and alleviating ulcer pain of the patients in the treatment of MiRAU without significant side effects.